Abstract:The enormous diversity of proteoforms produces tremendous complexity within cellular proteomes, facilitates intricate networks of molecular interactions, and constitutes a formidable analytical challenge for biomedical researchers. Currently, quantitative whole-proteome profiling often relies on non-targeted liquid chromatography-mass spectrometry (LC-MS), which samples proteoforms broadly, but can suffer from lower accuracy, sensitivity, and reproducibility compared with targeted LC-MS. Recent advances in bottom-up proteomics using targeted LC-MS have enabled previously unachievable identification and quantification of target proteins and posttranslational modifications within complex samples. Consequently, targeted LC-MS is rapidly advancing biomedical research, especially systems biology research in diverse areas that include proteogenomics, interactomics, kinomics, and biological pathway modeling. With the recent development of targeted LC-MS assays for nearly the entire human proteome, targeted LC-MS is positioned to enable quantitative proteomic profiling of unprecedented quality and accessibility to support fundamental and clinical research. Here we review recent applications of bottom-up proteomics using targeted LC-MS for systems biology research. SIGNIFICANCE: Advances in targeted proteomics are rapidly advancing systems biology research. Recent applications include systems-level investigations focused on posttranslational modifications (such as phosphoproteomics), protein conformation, protein-protein interaction, kinomics, proteogenomics, and metabolic and signaling pathways. Notably, absolute quantification of metabolic and signaling pathway proteins has enabled accurate pathway modeling and engineering. Integration of targeted proteomics with other technologies, such as RNA-seq, has facilitated diverse research such as the identification of hundreds of "missing" human proteins (genes and transcripts that appear to encode proteins but direct experimental evidence was lacking).

The emerging role of mass spectrometry-based proteomics in drug discovery

Proteomic methods for drug target discovery

Biochemical applications of mass spectrometry in pharmaceutical drug discovery

Emerging mass spectrometry-based proteomics methodologies for novel biomedical applications

Advances in mass spectrometry applied to pharmaceutical metabolomics

Chemical proteomics accelerates the target discovery of natural products

Mass spectrometry‐based high‐throughput proteomics and its role in biomedical studies and systems biology

Proteomics： a New Approach for Drug Discovery

Identification and characterization of molecular targets of natural products by mass spectrometry.

Emerging affinity methods for protein-drug interaction analysis

[Chemical Proteomics and Discovery of Drug Targets].

Advances in high‐resolution mass spectrometry applied to pharmaceuticals in 2020: A whole new age of information

Mass spectrometry in drug metabolism and pharmacokinetics: Current trends and future perspectives

Metabolite-protein interactions: Native mass spectrometry and collision induced affinity selection mass spectrometry in natural product screening

Mass Spectrometry–Based Proteogenomics: New Therapeutic Opportunities for Precision Medicine

Mass spectrometry for translational proteomics: progress and clinical implications

Chemoproteomics and Chemical Probes for Target Discovery

The role of mass spectrometry in the characterization of biologic protein products

Therapeutic Target Identification and Drug Discovery Driven by Chemical Proteomics

Application of targeted mass spectrometry in bottom-up proteomics for systems biology research

Metabolomics in Preclinical Drug Safety Assessment: Current Status and Future Trends